sq 28603 has been researched along with loratadine in 1 studies
| Studies (sq 28603) | Trials (sq 28603) | Recent Studies (post-2010) (sq 28603) | Studies (loratadine) | Trials (loratadine) | Recent Studies (post-2010) (loratadine) |
|---|---|---|---|---|---|
| 35 | 0 | 0 | 1,317 | 462 | 339 |
| Protein | Taxonomy | sq 28603 (IC50) | loratadine (IC50) |
|---|---|---|---|
| Cytochrome P450 2C19 | Homo sapiens (human) | 0.016 | |
| Histamine H1 receptor | Homo sapiens (human) | 0.23 | |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 0.245 | |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 0.1717 | |
| Bile acid receptor | Homo sapiens (human) | 3.07 | |
| Sodium-dependent neutral amino acid transporter B(0)AT2 | Homo sapiens (human) | 4 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Morphy, R; Rankovic, Z | 1 |
1 review(s) available for sq 28603 and loratadine
| Article | Year |
|---|---|
Designed multiple ligands. An emerging drug discovery paradigm.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Anti-Allergic Agents; Anti-Inflammatory Agents, Non-Steroidal; Antidepressive Agents; Antihypertensive Agents; Antipsychotic Agents; Chemistry, Pharmaceutical; Dopamine D2 Receptor Antagonists; Drug Design; Humans; Ligands; Metabolic Diseases; Peroxisome Proliferator-Activated Receptors; Receptors, Histamine H1; Selective Serotonin Reuptake Inhibitors | 2005 |